These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 22242462)
1. [Intestinal lymphatic transport of breviscapine orally administered in rat]. Gong YJ; Wang JX; Zhang Y; Shen M; Fu CM; Shen T Yao Xue Xue Bao; 2011 Oct; 46(10):1262-7. PubMed ID: 22242462 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of breviscapine liposomes following intravenous injection in Beagle dogs]. Lo WL; Guo JX; Ping QN; Li J; Zhao CW; Zhang L Yao Xue Xue Bao; 2006 Jan; 41(1):24-9. PubMed ID: 16683523 [TBL] [Abstract][Full Text] [Related]
3. Examination of lymphatic transport of puerarin in unconscious lymph duct-cannulated rats after administration in microemulsion drug delivery systems. Wu H; Zhou A; Lu C; Wang L Eur J Pharm Sci; 2011 Mar; 42(4):348-53. PubMed ID: 21216284 [TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of breviscapine liposomes in dogs, rabbits and rats. Lv W; Guo J; Ping Q; Song Y; Li J Int J Pharm; 2008 Jul; 359(1-2):118-22. PubMed ID: 18502062 [TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics of breviscapine and its beta-cyclodextrin complex in rats]. Zhang HY; Ping QN; Guo JX; Cao F Yao Xue Xue Bao; 2005 Jun; 40(6):563-7. PubMed ID: 16144326 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats. Huang JM; Weng WY; Huang XB; Ji YH; Chen E Eur J Drug Metab Pharmacokinet; 2005; 30(3):165-70. PubMed ID: 16250252 [TBL] [Abstract][Full Text] [Related]
7. [The effect of polyamidoamine (PAMAM) dendrimers on the solubility and pharmacokinetics of breviscapine]. Lu JJ; Wu ZH; Ping QN Yao Xue Xue Bao; 2009 Feb; 44(2):197-202. PubMed ID: 19408693 [TBL] [Abstract][Full Text] [Related]
8. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU. White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095 [TBL] [Abstract][Full Text] [Related]
9. [Comparison of the distribution of breviscapine in the brain by different administration routes]. Shi SL; Xu LY; Wu JJ; Li CY; Ge WH; Dai WY Yao Xue Xue Bao; 2009 May; 44(5):515-8. PubMed ID: 19618729 [TBL] [Abstract][Full Text] [Related]
10. [Enhanced absorption of breviscapine photosomes in small intestine of rats]. Tang XQ; Yang XL Zhongguo Zhong Yao Za Zhi; 2005 Feb; 30(3):222-5. PubMed ID: 15719646 [TBL] [Abstract][Full Text] [Related]
11. Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system. Ma Y; Li H; Guan S Drug Dev Ind Pharm; 2015 Feb; 41(2):177-82. PubMed ID: 25113432 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic and tissue distribution study of scutellarin in rats]. You HS; Dong YL; Xing JF; Zhang CL; Wang MY Zhongguo Zhong Yao Za Zhi; 2007 Aug; 32(16):1688-92. PubMed ID: 18027669 [TBL] [Abstract][Full Text] [Related]
13. Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism. Wang X; Zhang C; Han N; Luo J; Zhang S; Wang C; Jia Z; Du S Drug Deliv; 2021 Dec; 28(1):1664-1672. PubMed ID: 34338567 [TBL] [Abstract][Full Text] [Related]
14. Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system. Zhou Y; Ning Q; Yu DN; Li WG; Deng J J Pharm Pharmacol; 2014 Jul; 66(7):903-11. PubMed ID: 24697705 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of scutellarin in rabbits]. Li S; Jiang X; Yang Q; Jin Z Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Dec; 20(4):692-4. PubMed ID: 14716879 [TBL] [Abstract][Full Text] [Related]
16. [Study on the pharmacokinetics of scutellarin in dogs]. Jiang XH; Li SH; Lan K; Yang JY; Zhou J Yao Xue Xue Bao; 2003 May; 38(5):371-3. PubMed ID: 12958843 [TBL] [Abstract][Full Text] [Related]
17. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. Porter CJ; Charman SA; Charman WN J Pharm Sci; 1996 Apr; 85(4):351-6. PubMed ID: 8901067 [TBL] [Abstract][Full Text] [Related]
18. The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol. Caliph SM; Faassen FW; Porter CJ J Pharm Pharmacol; 2014 Oct; 66(10):1377-87. PubMed ID: 24821499 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction between scutellarin and valsartan in rats. Cui MY; Tian CC; Ju AX; Zhang CT; Li QH Yao Xue Xue Bao; 2013 Apr; 48(4):541-6. PubMed ID: 23833943 [TBL] [Abstract][Full Text] [Related]
20. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Gershkovich P; Qadri B; Yacovan A; Amselem S; Hoffman A Eur J Pharm Sci; 2007 Aug; 31(5):298-305. PubMed ID: 17560096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]